|
Workshop
[Free Online workshop] Immunogenicity of Biologic Drugs – Clinical Relevance case studies, Predictive Tools & Challenges with New modalities
Speakers:
Steve Swanson, Genentech; Yi Wen , Eli Lilly; Francesca Civoli , Coherus BioSciences; Vibha Jawa , BMS; Wenyu Liu , Genentech; Lin-zhi Chen ,Boehringer Ingelheim Pharmaceuticals, Inc.; Mauricio Maia, Genentech; Sofie Pattyn, ImmunXperts; Cathie (Dong) Xiang, Amgen; Ronit Mazor, FDA; João Pedras-Vasconcelos, FDA; Morten Nielsen, EIR Sciences, DTU
Organizers:
Ola Saad, Sivan Cohen and Surinder Kaur (Genentech, Inc.)
Date:
2022-09-15- 09/16/2022
Time:
8:30-12:30 Pacific Time
Registration fee:
Free
Location:
Online via zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2022-09-14
(it will close sooner if the seating cap is reached)
About the Topic
The Immunogenicity of Biologic Drugs workshop is a 2 half-day program aimed to promote the discussion and exchange of scientific ideas from the FDA and leading industry and academic experts on the application and clinical relevance of immunogenicity mitigation and assessment assays. Tentative topics covered in this workshop include, but are not limited to:
-
ADA assay Development, Validation, and interpretation (drug and target interference, pre-existing antibodies)
-
Advancements of predictive immunogenicity risk tools (in vitro, in silico) and lessons learned with implementation
-
Bioanalytical Strategies for New Modalities
-
Highlights from and comments around 2022 FDA Immunogenicity Labeling Draft Guidance
Note: This is an online meeting, The Zoom link will be sent to the registrants 1+ days before the event. About the Speakers
- Steve Swanson (Senior Principal Scientist, Genentech)
- Yi Wen (Advisor, Eli Lilly)
- Francesca Civoli (Vice President Bioanalytical Sciences, Coherus BioSciences)
- Vibha Jawa (Executive Director, BMS)
- Wenyu Liu (Senior Scientist, Genentech)
- Lin-zhi Chen (Sr. Research Fellow/ Bioanalytical Group Leader, Boehringer Ingelheim Pharmaceuticals, Inc.)
- Mauricio Maia (Senior Principal Scientist, Genentech)
- Sofie Pattyn (Chief Technology Officer, ImmunXperts a Q2 Solutions Company)
- Cathie (Dong) Xiang (Amgen)
- Morten Nielsen (CEO EIR Sciences; Professor at DTU - Technical University of Denmark)
- Ronit Mazor (Principal Investigator, CBER, FDA)
- João Pedras-Vasconcelos (Product Quality and Immunogenicity Senior Staff Fellow, CDER, FDA)
Agenda:
Sep. 15th
Time (PDT)
|
Time (EST)
|
Topic
|
Presenter
|
8:30-8:45 am
|
11:30-11:45am
|
Welcome & Workshop Introduction
|
Ola Saad & Sivan Cohen
|
8:45-9:15 am
|
11:45-11:15am
|
Immunogenicity Risk Assessments to Drive the Bioanalytical Strategy for Novel Modalities
|
Vibha Jawa, Executive Director, BMS
|
9:15-9:45 am
|
12:15-12:45pm
|
Immunogenicity of AAV Vectors in Gene Therapy
|
Ronit Mazor, Principal Investigator, CBER, FDA
|
9:45-10:15 am
|
12:45-1:15 pm
|
Recent Updates to HLA-II Prediction Algorithms, and Their Application to Assess the Immunogenicity Risk of Biotherapeutics
|
Morten Nielsen, CEO EIR Sciences; Professor at DTU
|
10:15-10:30am
|
1:15-1:30pm
|
Break
|
- |
10:30-11:00am
|
1:30-2:00pm
|
Early In Vitro Immunogenicity Assessment Tools
|
Sofie Pattyn, Chief Technology Officer, ImmunXperts a Q2Solutions Company
|
11:00-11:30am
|
2:00-2:30pm
|
DC Internalization and Innate Activation for Immunogenicity Risk Assessment of Antibodies
|
Yi Wen, Advisor, Eli Lilly
|
11:30-12:00pm
|
2:30-3:00pm
|
Use of In Vitro Cell Based Assays to Assess Potential Immunogenicity Risk of Critical Quality Attributes
|
Cathie (Dong) Xiang, Scientist, Amgen
|
12:00-12:30pm
|
3:00-3:30pm
|
PANEL DISCUSSION
|
All speakers
|
Sep. 16th
Time (PDT)
|
Time (EST)
|
Topic
|
Presenter
|
8:30 -8:45 am
|
11:30-11:45am
|
Day 2 Welcome & Introduction
|
Ola Saad & Sivan Cohen
|
8:45 -9:15 am
|
11:45-11:15am
|
Immunogenicity of Biologic Therapeutics & Clinical Relevance
|
Steve Swanson, Senior Principal Scientist, Genentech
|
9:15 -9:45 am
|
12:15-12:45pm
|
Immunogenicity Information in Labeling- Highlights from the New FDA Draft Guidance
|
João Pedras-Vasconcelos, Product Quality and Immunogenicity Senior Staff Fellow, CDER, FDA
|
9:45-10:15 am
|
12:45-1:15 pm
|
LC/MS for ADA Analysis: Simultaneous Quantitation and Isotyping and Beyond
|
Lin-zhi Chen, Sr. Research Fellow/ Bioanalytical Group Leader; Boehringer Ingelheim Pharmaceuticals, Inc.
|
10:15-10:30am
|
1:15-1:30pm
|
Break
|
|
10:30-11:00am
|
1:30-2:00pm
|
Investigating the Clinical Relevance of the Immunogenicity for a Bispecific Antibody
|
Wenyu Liu, Senior Scientist, Genentech
|
11:00-11:30am
|
2:00-2:30pm
|
Challenges in the Assessment of Biosimilar Immunogenicity Data
|
Francesca Civoli, Vice President Bioanalytical Sciences, CoherusBioSciences
|
11:30-12:00pm
|
2:30-3:00pm
|
Immunogenicity Profile of the Port Delivery System with Ranibizumab
|
Mauricio Maia Senior Principal Scientist, Genentech
|
12:00-12:30pm
|
3:00-3:30pm
|
PANEL DISCUSSION
|
All Speakers
|
2024-08-14, [Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)
|
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
|
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
|
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapeutics
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Simulations Plus
GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
|
Submit a Text Ad
|